| Today's Big NewsAug 4, 2023 |
|
Wednesday, September 6, 2023 | 2:00 PM ET / 11:00 AM PT Attendees will learn about the latest tools for interacting with medical images, how to guide readers through labeling workflows, and streamlining adjudication and data standardization. Discussions will include real-world use cases of how pharma companies are enhancing AI development by optimizing reader workflows. Register now.
|
|
| By Angus Liu In their ongoing RET inhibitor rivalry, Eli Lilly is pulling further ahead of Blueprint Medicines, even as the latter company is being abandoned by Roche. |
|
|
|
By James Waldron Mesoblast’s second attempt to win over regulators to its off-the-shelf cell therapy has had no more success than the first try, sinking the Australian biotech’s stock. |
By Conor Hale Johnson & Johnson MedTech's Biosense Webster division has secured a broad approval from the FDA that enables several of its atrial fibrillation treatments to be used without real-time radiation. |
By Kevin Dunleavy When Amgen launched the first biosimilar to compete with AbbVie’s Humira in the U.S., the company looked forward to six months of exclusivity in competing one-on-one against the immunology powerhouse. But Thursday, Amgen reported second-quarter sales of just $19 million for Amjevita, a 63% drop sequentially. |
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
By Fraiser Kansteiner In a bid to thwart shortages of critical drugs, Pfizer is relegating certain products made in Rocky Mount, North Carolina, to its emergency ordering list. The move comes after a tornado hit the company's injectables facility late last month, creating questions about potential supply disruptions. |
By Max Bayer One of Amgen's top BiTE molecules continues to inch forward after the company posted a brief phase 2 readout Thursday. The trial update included no new data, but Amgen said tarlatamab posted better safety and efficacy data than it produced in phase 1. |
By Zoey Becker The company is sticking to its ambitions of pulling a third of its revenue from its oncology portfolio by 2030. This year, the company expects $3 billion to come from its cancer trio of Trodelvy, Tecartus and Yescarta. |
By Conor Hale The DNA sequencing developer has begun shipping its first short-read hardware—while simultaneously announcing a new deal to boost those capabilities in the future. |
By Helen Floersh The company is tripling down on its Alzheimer’s franchise, rounding out its tau-focused pipeline with a gene therapy aimed at amyloid-beta plaques. |
By Max Bayer,Gabrielle Masson,Annalee Armstrong CBER chief Peter Marks doesn't have any plans to leave the FDA—yet. Anthony Fauci's replacement at NIAID has been founf. Jamie Rubin takes CFO role at Boundless after EQRx stint. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss how to support patients during the cancer drug shortage, plus this week's headlines. |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperLeading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| WhitepaperLearn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
